Polysorbate 80 and Helicobacter pylori: A microbiological and ultrastructural study

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Figura, Natale ^a   Marcolongo, Roberto ^b   Cavallo, Giovanni ^c   Santucci, Annalisa ^a   Collodel, Giulia ^a   Spreafico, Adriano ^a   Moretti, Elena ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Centre for Biochemical and Clinical Study of Rheumatic Diseases   (Italy)

^c Qi Srl   (Italy)

Author keywords

Antibiotics; Bacteria; Chemoresistances; Polysorbate 80; Transmission electron microscopy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; POLYSORBATE 80; TETRACYCLINE;

AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BROTH DILUTION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DISK DIFFUSION; DRUG MECHANISM; DRUG POTENTIATION; HELICOBACTER PYLORI; HUMAN; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SERUM; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, TRANSMISSION; POLYSORBATES; SURFACE-ACTIVE AGENTS;

BOVINAE; HELICOBACTER PYLORI;

EID: 84866510841     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-217     Document Type: Article

References (39)

1. Immunobiology of Helicobacter pylori infection. Telford JL, Covacci A, Rappuoli R, Ghiara P, Curr Opin Immunol 1997 9 498 503 10.1016/S0952-7915(97) 80101-X 9287174
2. Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Walker MM, Crabtree JE, Ann N Y Acad Sci 1998 859 96 111 10.1111/j.1749-6632.1998.tb11114.x 9928373
3. Basis for the management of drug-resistant Helicobacter pylori infection. Mégraud F, Drugs 2004 64 1893 1904 10.2165/00003495-200464170-00003 15329036
4. Pathogenesis of Helicobacter pylori infection. Kusters JG, van Vliet AH, Kuipers EJ, Clin Microbiol Rev 2006 19 449 490 10.1128/CMR.00054-05 16847081
5. Treatment of Helicobacter pylori infection 2010. O'Connor A, Gisbert JP, McNamara D, O'Morain C, Helicobacter 2010 15 46 52 21054653
6. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D, Am J Gastroenterol 2009 104 3069 3079 10.1038/ajg.2009.555 19844205
7. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group, Lancet 2011 377 905 913 10.1016/S0140-6736(11)60020-2 21345487
8. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Parente F, Cucino C, Bianchi PG, Dig Liver Dis 2003 35 523 528 10.1016/S1590-8658(03)00268-8 14567454
9. Worldwide H. pylori antibiotic resistance: a systematic review. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A, J Gastrointestin Liver Dis 2010 19 409 414 21188333
10. Treatment of Helicobacter pylori. Selgrad M, Malfertheiner P, Curr Opin Gastroenterol 2011 27 565 570 10.1097/MOG.0b013e32834bb818 21946029
11. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Fischbach L, Evans EL, Aliment Pharmacol Ther 2007 26 343 357 10.1111/j.1365-2036.2007. 03386.x 17635369
12. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG, Am J Gastroenterol 2000 95 3393 3398 10.1111/j.1572-0241.2000.03349.x 11151867
13. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Treiber G, Malfertheiner P, Klotz U, Expert Opin Pharmacother 2007 8 329 350 10.1517/14656566.8.3.329 17266468
14. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. Vítor JMB, Vale FF, FEMS Immunol Med Microbiol 2011 63 153 164 10.1111/j.1574-695X.2011.00865.x 22077218
15. Antimicrobial activity of a food-grade fully dilutable microemulsion against Escherichia coli and Staphylococcus aureus. Zhang H, Shen Y, Weng P, Zhao G, Feng F, Zheng X, Int J Food Microbiol 2009 135 211 215 10.1016/j.ijfoodmicro.2009.08.015 19717202
16. Certain surfactants show promise in the therapy of pulmonary tuberculosis. Stoops JK, Arora R, Armitage L, Song L, Blackburn MR, Krueger GR, Risin SA, In Vivo 2010 24 687 694 20952734
17. Therapeutics used to alleviate peptic ulcers inhibit H. pylori receptor binding in vitro. Huesca M, Gold B, Sherman P, Lewin P, Lingwood C, Zentralbl Bakteriol 1993 280 244 252 10.1016/S0934-8840(11)80962-X 8280948
18. Antimicrobial resistance incidence and risk factors among Helicobacter pylori -infected persons, United States. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J, Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD, Emerg Infect Dis 2004 10 1088 1094 10.3201/eid1006.030744 15207062
19. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Björkholm B, Sjolund M, Falk PG, Berg OG, Engstrand L, Andersson DI, Proc Natl Acad Sci USA 2001 98 14607 14612 10.1073/pnas.241517298 11717398
20. DNA damage triggers genetic exchange in Helicobacter pylori. Dorer MS, Fero J, Salama NR, PLoS Pathog 2010 6 1001026 10.1371/journal.ppat.1001026 20686662
21. Strain-specific genes of Helicobacter pylori: genome evolution driven by a novel type IV secretion system and genomic island transfer. Fischer W, Windhager L, Rohrer S, Karnholz A, Hoffmann R, Zimmer R, Haas R, Nucleic Acids Res 2010 38 6089 6101 10.1093/nar/gkq378 20478826
22. In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. Ndip RN, Malange Tarkang AE, Mbullah SM, Luma HN, Malongue A, Ndip LM, Nyongbela K, Wirmum C, Efange SM, J Ethnopharmacol 2007 114 452 457 10.1016/j.jep.2007.08.037 17913416
23. The oral administration of polysorbate 80 to the immature female rat does not increase uterine weight. Williams J, Odum J, Lewis RW, Brady AM, Toxicol Lett 1997 91 19 24 10.1016/S0378-4274(96)03863-5 9096282
24. Evaluation of developmental neurotoxicity of polysorbate 80 in rats. Ema M, Hara H, Matsumoto M, Hirata-Koizumi M, Hirose A, Kamata E, Reprod Toxicol 2008 25 89 99 10.1016/j.reprotox.2007.08.003 17961976
25. Composition and function of Helicobacter pylori outer membrane vesicles. Parker H, Keenan JI, Microbes Infect 2012 14 9 16 10.1016/j.micinf.2011.08.007 21911076
26. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro-an ultrastructural study. Armstrong JA, Wee SH, Goodwin CS, Wilson DH, J Med Microbiol 1987 24 343 350 10.1099/00222615-24-4-343 3694664
27. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Chey WD, Wong BC, Am J Gastroenterol 2007 102 1808 1825 10.1111/j.1572-0241.2007.01393.x 17608775
28. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Marais A, Bilardi C, Cantet F, Mendz GL, Mégraud F, Res Microbiol 2003 154 137 144 10.1016/S0923-2508(03)00030-5 12648728
29. Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori. Tsugawa H, Suzuki H, Muraoka H, Ikeda F, Hirata K, Matsuzaki J, Saito Y, Hibi T, Biochem Biophys Res Commun 2011 404 656 660 10.1016/j.bbrc.2010.12.034 21147064
30. A Helicobacter pylori TolC efflux pump confers resistance to metronidazole. van Amsterdam K, Bart A, van der Ende A, Antimicrob Agents Chemother 2005 49 1477 1482 10.1128/AAC.49.4.1477-1482.2005 15793129
31. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. Liu ZQ, Zheng PY, Yang PC, World J Gastroenterol 2008 14 5217 5222 10.3748/wjg.14.5217 18777600
32. Comparative genomics of microbial drug efflux systems. Paulsen IT, Chen J, Nelson KE, Saier MH Jr, J Mol Microbiol Biotechnol 2001 3 145 150 11321566
33. Alignment and structure prediction of divergent protein families: periplasmic and outer membrane proteins of bacterial efflux pumps. Johnson JM, Church GM, J Mol Biol 1999 287 695 715 10.1006/jmbi.1999.2630 10092468
34. Outer membrane permeability and antibiotic resistance. Delcour AH, Biochim Biophys Acta 2009 1794 808 816 10.1016/j.bbapap.2008.11.005 19100346
35. Agents that increase the permeability of the outer membrane. Vaara M, Microbiol Rev 1992 56 395 411 1406489
36. Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Savage PB, Ann Med 2001 33 167 171 10.3109/07853890109002073 11370769
37. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK, J Gastroenterol Hepatol 2011 26 825 828 10.1111/j.1440-1746.2011.06660.x 21251064
38. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE, Antimicrob Agents Chemother 2000 44 248 254 10.1128/AAC.44.2. 248-254.2000 10639345
39. Molecular basis of bacterial outer membrane permeability revisited. Nikaido H, Microbiol Mol Biol Rev 2003 67 593 656 10.1128/MMBR.67.4.593-656.2003 14665678